Persistently high serum H-FABP levels at admission and discharge in patients with chronic heart failure were associated with a significantly increased risk of cardiac events (HR 5.68).
Cohort (n=113)
No
Does persistently high serum H-FABP predict adverse clinical outcomes in patients with chronic heart failure?
Persistently elevated serum H-FABP levels at discharge in patients with chronic heart failure independently predict a higher risk of cardiac death and readmission.
Hazard Ratio: 5.68
Absolute Event Rate: 50.9% vs 9.8%
p-value: p=0.012
BACKGROUND: Heart-type fatty acid-binding protein (H-FABP) is a small cytosolic protein that is released into the circulation when the myocardium is injured. This study examined whether serial measurement of the H-FABP level provides additional prognostic information. METHODS AND RESULTS: Serum H-FABP levels were measured in 113 consecutive chronic heart failure (CHF) patients at both admission and discharge. The following 3 patterns of changes were identified. In 41 patients, H-FABP levels ( or =4.3 ng/ml) at admission, and in 21 of them (29%), H-FABP decreased to the normal range at discharge (Group 2), whereas 51 had persistently high H-FABP levels despite improvement in symptoms and signs of CHF (Group 3). There were 33 cardiac events (29%) during the follow-up period, and Group 3 had significantly higher cardiac event rates than Groups 1 and 2 (p=0.0002). Group 3 had the highest cardiac risk among the groups (hazard ratio 5.68, p=0.012). CONCLUSION: Serial measurement of the H-FABP level is a new monitoring tool that provides information to guide optimal therapy and management of CHF patients.
Niizeki et al. (2007) conducted a cohort in Chronic heart failure (n=113). Persistently high serum H-FABP levels vs. Normal or decreased H-FABP levels was evaluated on Cardiac events (cardiac death or worsening CHF requiring readmission) (HR 5.68, p=0.012). Persistently high serum H-FABP levels at admission and discharge in patients with chronic heart failure were associated with a significantly increased risk of cardiac events (HR 5.68).